WO1991018101A1 - Procede de production d'une proteine - Google Patents
Procede de production d'une proteine Download PDFInfo
- Publication number
- WO1991018101A1 WO1991018101A1 PCT/JP1991/000626 JP9100626W WO9118101A1 WO 1991018101 A1 WO1991018101 A1 WO 1991018101A1 JP 9100626 W JP9100626 W JP 9100626W WO 9118101 A1 WO9118101 A1 WO 9118101A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- dna
- protein
- sequence
- atg
- vector
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 98
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 62
- 238000000034 method Methods 0.000 title claims description 27
- 230000008569 process Effects 0.000 title description 5
- 108020004414 DNA Proteins 0.000 claims abstract description 84
- 108010076504 Protein Sorting Signals Proteins 0.000 claims abstract description 30
- 239000013604 expression vector Substances 0.000 claims abstract description 16
- 241000193764 Brevibacillus brevis Species 0.000 claims abstract description 12
- 239000013598 vector Substances 0.000 claims description 23
- 239000002773 nucleotide Substances 0.000 claims description 13
- 125000003729 nucleotide group Chemical group 0.000 claims description 13
- 241000894006 Bacteria Species 0.000 claims description 10
- 238000004519 manufacturing process Methods 0.000 claims description 10
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 6
- 238000013519 translation Methods 0.000 claims description 5
- 241001037822 Bacillus bacterium Species 0.000 claims description 4
- 230000014621 translational initiation Effects 0.000 claims description 4
- 230000005026 transcription initiation Effects 0.000 claims description 3
- 239000013612 plasmid Substances 0.000 abstract description 13
- 108091005804 Peptidases Proteins 0.000 abstract description 5
- 238000013518 transcription Methods 0.000 abstract description 5
- 230000035897 transcription Effects 0.000 abstract description 5
- 108700026244 Open Reading Frames Proteins 0.000 abstract description 3
- 239000004365 Protease Substances 0.000 abstract description 3
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 abstract description 3
- 238000011084 recovery Methods 0.000 abstract description 3
- 238000011534 incubation Methods 0.000 abstract 2
- 108091026890 Coding region Proteins 0.000 abstract 1
- 235000018102 proteins Nutrition 0.000 description 57
- 239000002609 medium Substances 0.000 description 39
- 210000004027 cell Anatomy 0.000 description 27
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 26
- 125000003275 alpha amino acid group Chemical group 0.000 description 22
- 241000193830 Bacillus <bacterium> Species 0.000 description 17
- 229960003276 erythromycin Drugs 0.000 description 13
- 239000012634 fragment Substances 0.000 description 13
- 239000000243 solution Substances 0.000 description 13
- 239000006228 supernatant Substances 0.000 description 13
- 241000588724 Escherichia coli Species 0.000 description 12
- 108090000765 processed proteins & peptides Proteins 0.000 description 11
- 108010065511 Amylases Proteins 0.000 description 10
- 235000001014 amino acid Nutrition 0.000 description 10
- 150000001413 amino acids Chemical class 0.000 description 10
- GVUGOAYIVIDWIO-UFWWTJHBSA-N nepidermin Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CS)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C(C)C)C(C)C)C1=CC=C(O)C=C1 GVUGOAYIVIDWIO-UFWWTJHBSA-N 0.000 description 10
- 239000004382 Amylase Substances 0.000 description 9
- 102000013142 Amylases Human genes 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 101500025419 Homo sapiens Epidermal growth factor Proteins 0.000 description 9
- 235000019418 amylase Nutrition 0.000 description 9
- 229940116978 human epidermal growth factor Drugs 0.000 description 9
- 238000005119 centrifugation Methods 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 244000005700 microbiome Species 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 6
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 6
- 235000011130 ammonium sulphate Nutrition 0.000 description 6
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 5
- 101710098940 Pro-epidermal growth factor Proteins 0.000 description 5
- 238000010586 diagram Methods 0.000 description 5
- 239000002244 precipitate Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 230000014616 translation Effects 0.000 description 5
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 230000003248 secreting effect Effects 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 238000010353 genetic engineering Methods 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 244000063299 Bacillus subtilis Species 0.000 description 2
- 235000014469 Bacillus subtilis Nutrition 0.000 description 2
- 101100015323 Caenorhabditis elegans bre-1 gene Proteins 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 241001658031 Eris Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 239000001888 Peptone Substances 0.000 description 2
- 108010080698 Peptones Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 108020005038 Terminator Codon Proteins 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 235000013372 meat Nutrition 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 235000019319 peptone Nutrition 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 235000019833 protease Nutrition 0.000 description 2
- 235000019419 proteases Nutrition 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 101150094969 rfp1 gene Proteins 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 239000013605 shuttle vector Substances 0.000 description 2
- 230000001131 transforming effect Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 210000004885 white matter Anatomy 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 101150019828 42 gene Proteins 0.000 description 1
- RPABDKTXMKOGKI-OYTUFZPASA-N 6-methyl-n-[2-[(2s,5s,8s,11s,14s,17s,20s,23s)-8,11,14,20-tetrakis(2-aminoethyl)-5-[(1r)-1-hydroxyethyl]-17,23-bis(2-methylpropyl)-3,6,9,12,15,18,21,24-octaoxo-1,4,7,10,13,16,19,22-octazacyclotetracos-2-yl]ethyl]octanamide Chemical compound CCC(C)CCCCC(=O)NCC[C@@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H]([C@@H](C)O)NC1=O RPABDKTXMKOGKI-OYTUFZPASA-N 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 1
- 229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 108700010070 Codon Usage Proteins 0.000 description 1
- 108010078777 Colistin Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108060002716 Exonuclease Proteins 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 101000851176 Homo sapiens Pro-epidermal growth factor Proteins 0.000 description 1
- 101000740205 Homo sapiens Sal-like protein 1 Proteins 0.000 description 1
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 108010086093 Mung Bean Nuclease Proteins 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 102000015336 Nerve Growth Factor Human genes 0.000 description 1
- 108010025020 Nerve Growth Factor Proteins 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 description 1
- 102000008422 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 1
- 108010076181 Proinsulin Proteins 0.000 description 1
- 108010059712 Pronase Proteins 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 108091006629 SLC13A2 Proteins 0.000 description 1
- 102100037204 Sal-like protein 1 Human genes 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 102000004139 alpha-Amylases Human genes 0.000 description 1
- 108090000637 alpha-Amylases Proteins 0.000 description 1
- 229940024171 alpha-amylase Drugs 0.000 description 1
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 1
- 239000001099 ammonium carbonate Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 108010058966 bacteriophage T7 induced DNA polymerase Proteins 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- PWOSZCQLSAMRQW-UHFFFAOYSA-N beryllium(2+) Chemical compound [Be+2] PWOSZCQLSAMRQW-UHFFFAOYSA-N 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 229940019700 blood coagulation factors Drugs 0.000 description 1
- 235000021152 breakfast Nutrition 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000013611 chromosomal DNA Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940095399 enema Drugs 0.000 description 1
- 230000008472 epithelial growth Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 102000013165 exonuclease Human genes 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 229910002804 graphite Inorganic materials 0.000 description 1
- 239000010439 graphite Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 210000003000 inclusion body Anatomy 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012533 medium component Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000004897 n-terminal region Anatomy 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 238000001668 nucleic acid synthesis Methods 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000011426 transformation method Methods 0.000 description 1
- PIEPQKCYPFFYMG-UHFFFAOYSA-N tris acetate Chemical compound CC(O)=O.OCC(N)(CO)CO PIEPQKCYPFFYMG-UHFFFAOYSA-N 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2405—Glucanases
- C12N9/2408—Glucanases acting on alpha -1,4-glucosidic bonds
- C12N9/2411—Amylases
- C12N9/2414—Alpha-amylase (3.2.1.1.)
- C12N9/2417—Alpha-amylase (3.2.1.1.) from microbiological source
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/32—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bacillus (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
- C12N15/75—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for Bacillus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/8215—Microorganisms
- Y10S435/822—Microorganisms using bacteria or actinomycetales
- Y10S435/832—Bacillus
- Y10S435/833—Bacillus brevis
Definitions
- the present invention encodes a so-called signal peptide.
- the present invention relates to a DNA sequence and a method for producing a protein using the DNA sequence by genetic engineering. More specifically, the present invention relates to a method for producing a protein using Bacillus brevis as a host and a DNA sequence required for the method.
- the method of producing a heterologous protein using a microorganism or the like using the recombinant DNA technology is a technique that is currently widely used in the production of pharmaceuticals and the like.
- Escherichia coli is most commonly used as a host in such a method, but in the case of Escherichia coli and the like, the produced heterologous protein usually remains in the cell. . Therefore, in order to purify a heterologous protein, it is necessary to destroy cells and remove many E. coli-derived proteins and the like. In addition, a heterologous protein produced in large quantities in limited cells often forms inclusion bodies, and is required to regenerate the activity of this heterologous protein. It often requires a lot of effort.
- Bacillus * brevis 47 S
- Bacillus * brevis 47 S
- DNA encoding the gene is ligated to an exogenous gene such as human epidermal growth factor, and introduced into the bacterium les brevis 47. (1989) Proc. Nat]. Acad. Sci. USA 86, 3589-3593 has been reported to successfully secrete the exogenous gene product of H. Yamagata. ) 0
- This strain ⁇ Blevis 47 is produced because it secretes a small amount of proteinase outside the cells. There was a possibility that the exogenous gene product was degraded in the medium.
- the present invention has been made to solve the above problems, and has found a protein BBRP42 secreted in the early stage of culture, in which proteinase is not sufficiently secreted.
- a protein BBRP42 secreted in the early stage of culture, in which proteinase is not sufficiently secreted.
- the present invention first relates to a DNA encoding a signal peptide, and relates to a signal peptide substantially represented by the following sequence (I). It consists of the base sequence to be coded.
- the present invention also relates to an expression vector, and comprises a DNA encoding the above-mentioned signal peptide and a desired heterologous gene linked to its downstream end.
- the present invention relates to a method for producing a desired protein, wherein a host cell is transformed with the vector according to the present invention.
- the present invention is characterized in that a desired protein is secreted into a medium by culturing the transformant.
- the expression of the desired heterologous protein is achieved by ligating the DNA encoding the peptide of the present invention with the DNA encoding the desired heterologous protein and expressing it.
- the desired heterologous protein is produced in the medium prior to the protease that is derived from the genus Bacillus. High-yield, homogeneous protein production is possible o
- the figure shows the results of SDS-polyacrylamide gel electrophoresis performed on the protein secreted into the medium in the early stage of culture, obtained in Experimental Example 1.
- FIG. 2 is a diagram showing a restriction enzyme map of a DNA fragment containing a gene encoding BBRP42.
- Figure 3 shows the EcoRI force of ⁇ BRE-1, one of the fractionation mutants prepared in Example 3, the base sequence up to Hindm, and BBRP 4.
- Figure 2 shows the amino acid sequence of o.
- one force up to 13 base pairs and up to 1791 base pairs up to 1796 base pairs, originated from the vector. Represents the cloning side of
- ⁇ 2 is the origin of the secretory signal (translation start point).
- ⁇ 3 is the starting point of BBRP42.
- FIG. 4 is a diagram showing a process of creating an expression unit vector.
- FIG. 5 is a diagram showing the process of constructing a B. 1 icheni forniis unique amylase expression vector.
- FIG. 6 is a diagram showing a process of constructing a human epidermal growth factor expression vector.
- FIG. 7 shows the change in ⁇ -amylase activity secreted by V. cerevisiae 47 transformed by pAMY-3 with the cultivation time. It is a graph. In the figure,
- ⁇ 2 medium containing 10 ⁇ g / ml erythromycin —2 medium containing ⁇ ⁇ g Z ml of erythromycin ⁇ 2 medium 2 ⁇ 0 ⁇ g LS medium containing Z ml of erythromycin,-+-contains 2 ⁇ 0 g Z ml of erythromycin and 1% gnorecose
- FIG. 8 is a graph showing the change of h—EGF secreted by Bacillus ⁇ Blevis47 transformed by pEGF-2 according to the culture time.
- FIG. 9 is a diagram showing the amino acid sequence and its base sequence of a pronythurin derivative of Sanole.
- FIG. 10 shows the pattern of a protein transformed with pINT90d2 and the secreted protein.
- Figure 1 shows the results of analysis by stamping.
- Lane 1 is a procurement derivative of sal expressed in E. coli, lane 2.
- lane 2 In this study, we examined the secretion of vinoreles brevis 47. Arrows indicate prolinurine derivatives.
- the amino acid sequence has the above-mentioned sequence.
- the DNA according to the present invention is characterized by a peptide having an amino acid sequence that encodes such a strong force.
- amino acid sequence is substantially represented by the above-mentioned sequence (I)
- signal peptide This means that deletion, substitution, addition, etc. of 1 to 3 amino acids may be performed as much as possible.
- the amino acid sequence represented by this sequence (I) is a BBRP that is a protein secreted into the medium in the early stage of cultivation of Bacillus ⁇ brevis 47 when cultured. It has been completed based on the analysis of the gene encoding 42.
- BBRP 42 is a novel protein having the following properties
- a DNA encoding the signal peptide according to the present invention has a base sequence encoding the sequence (I), and a DNA encoding the signal peptide as described above. It has a nucleotide sequence corresponding to the change in the amino acid sequence of the peptide which has the following effect.
- a typical sequence of DNA according to the present invention is the following sequence ( ⁇ ).
- the DNA encoding the signal peptide according to the present invention includes the DNA whose base sequence is the above-described sequence ( ⁇ ) and the degenerate isomer thereof. is there .
- the term "degenerate isomer” refers to DNA that has the same nucleotide sequence and encodes the same peptide except that degenerate codons are used.
- nucleotide sequence of the DNA according to the present invention Since the nucleotide sequence of the DNA according to the present invention has been determined, one means for obtaining the DNA is produced according to a nucleic acid synthesis method. That is.
- a method of cutting out DNA from the generative DNA of the present invention can also be used.
- examples of such methods include the genomic library derived from Bacillus brevis 47, a method that has been used in the field of genetic engineering, For example, it can be obtained by the hybridization method using an appropriate probe. For specific examples of such a method, see the experimental examples described below.
- the DNA according to the present invention is a DNA encoding a signal peptide. Therefore, the DNA and the desired protein linked to the downstream end of the DNA are copied.
- Loading DNA If host and host cells are transformed in the form of DNA, particularly in the form of an expression vector, which is capable of replicating and expressing both genetic information in the host cell, the production of the protein outside the host cell It can help you get white matter.
- the DNA according to the present invention is constructed as a vector to be used in a host vector system using the genus Bacillus as a host. It is suitable for transforming and utilizing bacteria belonging to the genus Genus, in particular, N. cerevisiae. That is, the DNA according to the present invention is capable of producing a heterologous protein in the medium before the protease of the Bacillus genus is secreted into the medium. Power.
- the expression vector according to the present invention includes the above-described DNA encoding the peptide and a desired exogenous protein ligated to the downstream end thereof. It is characterized in that it incorporates DNA encoding white matter and has DNA necessary for expression of these exogenous genes.
- the expression vector according to the present invention is an expression vector to be used in a host-vector system using a bacterium belonging to the genus Bacillus. It is preferably constructed as
- Procedures or methods for constructing vectors according to the present invention may be those that are commonly used in the fields of molecular biology, biotechnology or genetic engineering. Good. For example, to code a signal peptide according to the present invention
- the vector according to the present invention is obtained by the following operation. The power to gain. Immediately, the DNA obtained by screening from the BBRP 42 gene library described above is incorporated into a vector that can be replicated in E. coli or the like. The obtained DNA can be replicated in the intended host by linking the obtained DNA with a DNA encoding the desired heterologous protein at its downstream end. By incorporating it into a vector, the vector according to the present invention can be obtained.
- pTA106, pUB110, and pE19 are vectors that can be replicated by the Bacillus bacterium. 4, plasmids such as pC194, and the DNA derived therefrom.
- the microorganisms used in the gene library and in the process of cloning the DNA encoding the obtained signal peptide For example, Escherichia coli, and a vector that can be replicated by both a microorganism used as a host in the production of a protein, for example, a bacterium belonging to the genus Bacillus, that is, a vector that can be replicated. It is also preferable to use ⁇ and ⁇ because the operation of transferring the DNA fragment can be omitted.
- E. coli and bacteria belonging to the genus Bacillus include, for example, pH13.
- these plasmids need to include selection markers, and as an example of those selection markers, the Chrome Fenni These include nore resistance, erythromycin resistance, neomycin resistance, tetracycline resistance, and streptmycin resistance.
- the expression vector according to the present invention is used for the purpose of actually introducing it into a host cell to secrete and express a desired heterologous protein.
- DNA required for the expression of exogenous genes consisting of DNA encoding a heterologous protein and a heterologous protein, that is, a promoter, a transcription initiation signal, and a ribosome binding site.
- a translation control signal such as a translation stop signal and a transcription termination signal, and a translation control signal.
- the regulator of that origin vector may be used as is. And power.
- the signal peptide may be encoded. It is advantageous to clone and use not only DNA but also regulatory regions such as promoters.
- a promoter that expresses these exogenous genes be incorporated at the beginning of the culture. is there .
- Preferred Promoter Specific examples of —i 2 — include those having at least 30 base pairs or more in the following base sequence (m).
- nucleotide sequence between the transcription initiation point and the translation initiation point was defined as the DNA required for the expression of the exogenous gene.
- It preferably contains a translation control signal represented by (IV).
- the heterologous protein produced in the present invention is not particularly limited. Specific examples thereof include h-EGF described in the above-mentioned literature, which produced an exogenous protein using vinoreles brevis 47, as well as interferon and various types of interferon. -Loinin, insulin, NGF, TNF, GM—CSF, blood coagulation factor factor VI, and specific antigen proteins for various diseases.
- the method for producing a desired protein according to the present invention comprises transforming a host microorganism with the expression vector according to the present invention, and culturing the transformant.
- the present invention is characterized in that the protein is secreted into the medium.
- Bacteria especially Bacillus bacteria, are used as host microorganisms. Yes.
- Bacillus bacterium include Bacillus brevisca.
- Transformation methods may be those commonly used in this field.
- the desired exogenous protein is produced and accumulated outside the cells of the microorganism (that is, in the culture medium).
- Culturing or culturing conditions of the transformant is essentially the same as that for the host microorganism used.
- recovery and purification of a desired protein from a culture solution can be performed strongly according to a conventional method.
- the cells were diluted with Tlura medium 1-fold and shake-cultured at 37 ° C while measuring the absorbance at 660 nm.
- the loop is the DNA sequence of the gene predicted from the fourth to second ⁇ amino acid sequences obtained in Experimental Example 2, which is already a clone.
- the probe described above hybridized to a 6.6 kb fragment.
- the EcoRI fragment was inserted into the EcoRI site of pUC18 (manufactured by Takara Shuzo Co., Ltd.), and the DNA was prepared.
- a map was created (Fig. 2).
- the DNA cut with various restriction enzymes was subjected to Southern Neubridization using the above-mentioned probe. , 1.7 kb SacI-PstI fragment.
- a 3.7 kb Sa11-SphI fragment containing this region was inserted between Sal1 and Sphl sites of pHSG39 9 (Takara Shuzo) and obtained.
- the structure at the time was, in order from the N-terminal side, common to the Bacillus secretory signals already examined, in order from the hydrophilic site to the hydrophobic site. Position — well matched to the structure consisting of the cleavage site.
- PBRE-3 was created by altering with a pair of synthetic DNAs consisting of 5 '. This plasmid encodes the promoter of the gene encoding BBRP42, the signal peptide of BBRP42, and further downstream.
- NcoI NcoI
- BamHI Xbal
- Pstl Pstl
- SphlHindlE site By directly linking a heterologous protein gene to this NcoI site, one expression unit is created. I can be powerful. By cutting with N col, the DNA portion encoding the amino acid A1a at the end of the signal peptide is cut, and the gene is ligated. In this case, it is necessary to add Ala-encoding DNA to its 5 'end. In addition, since this plasmid cannot be replicated during a batch resynthesis, the expression unit created on pBRE-3 must be replaced with a batch It must be moved to a replica that can be replicated in 4-7.
- plasmids that incorporate a heterologous protein gene into pBRE-3 DNA fragments excised with EcoRI and Hindm, can be used in plasmids such as pHP13. Must also be inserted into the appropriate site on a replicable shuttle vector.
- EXPERIMENTAL EXAMPLE 5 B. I. cheniformis is an amylase expression vector constructed and expressed in a yeast strain 47.
- B.1 i cheniform isa — a plasmid containing the amylase gene pTN1 (T. Yuuki. Et a 1. (1985) J. Biochem., 98, 1147—)
- the DNA fragment excised by BamHI and BeII was inserted into the BamHI side of pBRE — 3 created in Experimental Example 4, and the amamiase gene was oriented in the correct direction.
- PAMY12 was created by inserting the resulting pair of synthetic DNAs.
- p A ⁇ 2-2 is a promoter of the gene that encodes BBRP 42, a signal peptide of BBRP 42, and then an mirror of B. I icheniforniis. It has one expression unit that encodes cells. Furthermore, the DNA containing the expression unit was excised from pAMY-2 using EcoRI and HindIE, and one of the shuttle vectors of E. coli and B. subti1is was isolated.
- PAMY13 was created by inserting into the EcoRI, Hindm site. This plasmid was used to transform Noktilus ⁇ previs 47 according to the method of Takahashi et al. (J. Bacteriol, (1983) 156, 1130-1134). The resulting transformant was transformed into a T2 medium (1% peptone s 0.5% meat, yeast, 1% s / ml) containing 1 Q s / ml of Elysium Mycin. Planted on the gnore course) 3 7
- T2 medium containing 1 ⁇ ⁇ g Z ml of Eris mouth Mycin.
- T2 medium containing 200 ⁇ ⁇ / ml erythromycin, LS medium containing 2000 ml erythromycin (1% peptone, 0%
- the cells were inoculated in LS medium containing 0.5% yeast extract, 0.25% salt) or 1% gizoleose and 200; / g E. coli mycin, 37.
- Shaking culture was performed in C. A part of the culture solution was removed every 24 hours, and the supernatant from which the cells had been removed by centrifugation was used as an enzyme enzyme solution for activity measurement.
- the amylase activity in the supernatant was measured in the same manner as in Experimental Example 5 using the H. Fuwa method of Matsuzaki transformation.
- Figure 7 shows the time course of the amylase activity secreted into the supernatant. At 24 hours, secretion was best in LS medium containing 20 ⁇ g Z ml of erythromasin, followed by 200 g Z ml of erythromycin. T2 medium containing cin., LS medium containing 1% glucose and 200 ⁇ m of erythrocyte mycin, 1 ⁇ ⁇ g The order was T2 medium. However, the culture time was 72 hours.
- T2 medium containing 10 ⁇ g / ml of erythromycin.
- LS medium containing 200 ug / ml of erythromycin, and T2 medium containing 200 gyml of erythromycin.
- T 2 medium containing l O / U g Z ml of E. coli mouth secreted amylase from 920,000 liters per ml of T2 medium.
- Human epidermal growth factor is a relatively small polypeptide composed of 58 amino acids, and in this experimental example, the DNA encoding human epidermal growth factor was used as the human epidermal growth factor. A chemically synthesized product was used. When synthesizing DNA, the sequence that encodes the last A1a of the signal sequence is located upstream, the TAA that encodes the termination codon is located downstream, and both ends are included. , N co I and
- the DNAs compatible with the XbaI site were divided into four and synthesized. This synthetic DNA was inserted into the NcoI, XbaI site of pBRE-3 to create pEGF-1. This plasmid was cut out with the power of EcoRI and Hindin.
- F-2 was created.
- This expression vector was introduced into Bacillus brevis 47 similarly to Experimental Example 5.
- the obtained transformant was inoculated in a T2 medium containing 10 ⁇ g / ml of Eris-mouth Mycin, and cultured at 37 ° C with shaking. After removing the cells Inspection of h-EGF in the supernatant using an anti-h-EGF antibody confirmed the presence of h-EGF in the supernatant.
- T2 containing 10 g / ml of Escherichia coli with Batinores ⁇ transformed with pEGF-2 obtained in Experimental Example 7 The cells were inoculated into a medium and cultured at 37 C with shaking. A portion of the culture solution is removed every 24 hours, and the concentration of h-EGF in the supernatant, from which the cells have been removed by centrifugation, is adjusted to the level of human epithelial growth factor. Quantitation was performed using ELISA ⁇ £ (Current protocol in molecular biology Vol.2, Green Publishing Associates and Wiley-Interscience 1989) using a monoclonal antibody. As a standard sample, purified recombinant human EGF (manufactured by Ace Pharmaceutical Co., Ltd.) was used.
- Figure 8 shows the results.
- the amount of h — EGF increased up to 48 hours and did not increase with further cultures. At this time, the amount of h — E GF was 10 and 5 ⁇ g per 1 ml.
- Example 9 Purification of h-EGF secreted by Bacillus brevis 47 and confirmation of N-terminal amino acid sequence
- H secreted from T. chinores brevis 47. Confirmed whether the N-terminal signal peptide of EGF was cleaved correctly.
- H—EGF was purified.
- H EGF was eluted by the gradient of acetonitrile solution.
- h A fraction containing EGF was taken, and a part of the fraction was used to analyze the amino acid sequence of 20 N-terminal amino acids (ABI's 4777A).
- the resulting amino acid system Asn— Ser— Asp— Ser— Glu— X— Pro— Leu— Ser-His-Asp-Gly-Tyr-X-Leu-His-Asp-Gl- It was Val-X. X indicates a residue whose decoding is unknown.
- the amino acid residue at the N-terminus is Asn, which coincides with the residue at the N-terminus of human epidermal growth factor, confirming that the signal sequence was correctly cleaved.
- the residue whose decoding is unknown is a case where amino acid cannot be analyzed due to modification of amino acid, and a case where amino acid has Cys residue.
- the amino acid residues of human epidermal growth factor that correspond to the X residues in the amino acid sequence obtained in this study are all Cys residues. X corresponds to Cys, and the amino acid sequence of the N-terminal 20 amino acids of h-EGF secreted by Bacillus brevis 47 is correct. O It is concluded that the
- This derivative is located at the N-terminus of the salin procurin.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Description
Claims
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2/122166 | 1990-05-11 | ||
JP12216690 | 1990-05-11 | ||
JP2334575A JPH04126084A (ja) | 1990-05-11 | 1990-11-30 | 蛋白質の製造法 |
JP2/334575 | 1990-11-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1991018101A1 true WO1991018101A1 (fr) | 1991-11-28 |
Family
ID=26459349
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1991/000626 WO1991018101A1 (fr) | 1990-05-11 | 1991-05-10 | Procede de production d'une proteine |
Country Status (11)
Country | Link |
---|---|
US (1) | US5232841A (ja) |
EP (1) | EP0531530A1 (ja) |
JP (1) | JPH04126084A (ja) |
AU (1) | AU643793B2 (ja) |
CA (1) | CA2082637A1 (ja) |
CS (1) | CS135591A2 (ja) |
IE (1) | IE911607A1 (ja) |
IL (1) | IL98095A0 (ja) |
NZ (1) | NZ238095A (ja) |
PT (1) | PT97623A (ja) |
WO (1) | WO1991018101A1 (ja) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5714346A (en) * | 1993-02-22 | 1998-02-03 | Sumitomo Pharmaceuticals Company, Limited | Process for production of human growth hormone using Bacillus Brevis |
JP3406244B2 (ja) | 1999-04-30 | 2003-05-12 | 伊藤ハム株式会社 | 新規な融合蛋白質からの組み換えインスリンの製造方法 |
JP5020487B2 (ja) * | 2005-07-22 | 2012-09-05 | ヒゲタ醤油株式会社 | 融合タンパク質発現用新規dna及び該dnaを用いたタンパク質の製造方法 |
WO2007137300A2 (en) | 2006-05-23 | 2007-11-29 | Bellicum Pharmaceuticals, Inc. | Modified dendritic cells having enhanced survival and immunogenicity and related compositions and methods |
US8097422B2 (en) | 2007-06-20 | 2012-01-17 | Salk Institute For Biological Studies | Kir channel modulators |
US20090280103A1 (en) * | 2008-04-04 | 2009-11-12 | Martin Flueck | Regulation of muscle repair |
US20120156761A1 (en) | 2009-07-02 | 2012-06-21 | Verdezyne, Inc. | Biological methods for preparing adipic acid |
WO2011006126A2 (en) * | 2009-07-09 | 2011-01-13 | Verdezyne, Inc | Engineered microorganisms with enhanced fermentation activity |
US8889394B2 (en) * | 2009-09-07 | 2014-11-18 | Empire Technology Development Llc | Multiple domain proteins |
US8343752B2 (en) | 2011-05-03 | 2013-01-01 | Verdezyne, Inc. | Biological methods for preparing adipic acid |
US8728798B2 (en) | 2011-05-03 | 2014-05-20 | Verdezyne, Inc. | Biological methods for preparing adipic acid |
MY166952A (en) | 2011-07-06 | 2018-07-25 | Verdezyne Inc | Biological methods for preparing a fatty dicarboxylic acid |
CA2895130A1 (en) | 2012-12-19 | 2014-06-26 | Verdezyne, Inc. | Biological methods for preparing a fatty dicarboxylic acid |
EP2935563B1 (en) | 2012-12-19 | 2020-11-04 | Corvay Bioproducts GmbH | Biological methods for preparing a fatty dicarboxylic acid |
TWI638047B (zh) | 2014-04-09 | 2018-10-11 | 史基普研究協會 | 藉由核酸三磷酸酯轉運子將非天然或經修飾的核苷三磷酸酯輸入至細胞中 |
WO2016154046A2 (en) | 2015-03-20 | 2016-09-29 | Verdezyne, Inc. | Biological methods for preparing 3-hydroxypropionic acid |
TWI821192B (zh) | 2017-07-11 | 2023-11-11 | 美商新索思股份有限公司 | 非天然核苷酸之導入及其方法 |
WO2019014309A1 (en) | 2017-07-13 | 2019-01-17 | Verdezyne (Abc), Llc | BIOLOGICAL METHODS FOR MODIFYING A CELL CARBON FLOW |
BR112020002271A2 (pt) | 2017-08-03 | 2020-07-28 | Synthorx, Inc. | conjugados de citocina para o tratamento de doenças proliferativas e infecciosas |
WO2020060948A1 (en) | 2018-09-17 | 2020-03-26 | Levadura Biotechnology, Inc. | Production of cannabinoids in yeast using a fatty acid feedstock |
CN114949240A (zh) | 2019-02-06 | 2022-08-30 | 新索思股份有限公司 | Il-2缀合物及其使用方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0231682A (ja) * | 1988-01-25 | 1990-02-01 | Juzo Udaka | ヒトegfの製造法 |
-
1990
- 1990-11-30 JP JP2334575A patent/JPH04126084A/ja active Pending
-
1991
- 1991-05-08 CS CS911355A patent/CS135591A2/cs unknown
- 1991-05-09 IL IL98095A patent/IL98095A0/xx unknown
- 1991-05-09 NZ NZ238095A patent/NZ238095A/en unknown
- 1991-05-09 US US07/696,551 patent/US5232841A/en not_active Expired - Fee Related
- 1991-05-09 PT PT97623A patent/PT97623A/pt not_active Application Discontinuation
- 1991-05-10 CA CA002082637A patent/CA2082637A1/en not_active Abandoned
- 1991-05-10 IE IE160791A patent/IE911607A1/en unknown
- 1991-05-10 WO PCT/JP1991/000626 patent/WO1991018101A1/ja not_active Application Discontinuation
- 1991-05-10 AU AU77626/91A patent/AU643793B2/en not_active Ceased
- 1991-05-10 EP EP91920978A patent/EP0531530A1/en not_active Withdrawn
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0231682A (ja) * | 1988-01-25 | 1990-02-01 | Juzo Udaka | ヒトegfの製造法 |
Non-Patent Citations (2)
Title |
---|
Proc. Natl. Acad. Sci. USA, Vol. 86, No. 10, (1986) YAMAGATA H. et al. "Use of Bacillus-Brevis for Efficient Synthesis and Secretion of Human Epidermal Growth Factor" p. 3589-3593. * |
See also references of EP0531530A4 * |
Also Published As
Publication number | Publication date |
---|---|
AU7762691A (en) | 1991-12-10 |
PT97623A (pt) | 1992-02-28 |
NZ238095A (en) | 1992-10-28 |
IL98095A0 (en) | 1992-06-21 |
CS135591A2 (en) | 1991-12-17 |
AU643793B2 (en) | 1993-11-25 |
CA2082637A1 (en) | 1991-11-12 |
IE911607A1 (en) | 1991-11-20 |
EP0531530A4 (ja) | 1994-04-06 |
US5232841A (en) | 1993-08-03 |
EP0531530A1 (en) | 1993-03-17 |
JPH04126084A (ja) | 1992-04-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1991018101A1 (fr) | Procede de production d'une proteine | |
US4865974A (en) | Bacterial methionine N-terminal peptidase | |
US5922583A (en) | Methods for production of recombinant plasmids | |
FI100250B (fi) | Hirudiinijohdannaisten eritys | |
HU205386B (en) | Process for expressing cloned lysostaphin gene and for producing dna fragment containing the gene, expression vector and transformed host cell | |
EP0205475B2 (en) | Recombinant methods for production of serine protease inhibitors and dna sequences useful for same | |
WO1994021789A1 (en) | Expression of heterologous polypeptides in halobacteria | |
US5013662A (en) | Bacterial methionine n-terminal peptidase | |
HUT57263A (en) | Process for producing bacterial vectors | |
US4828988A (en) | Hybrid polypeptides comprising somatocrinine and alpha1 -antitrypsin, method for their production from bacterial clones and use thereof for the production of somatocrinine | |
Dittrich et al. | Production and secretion of recombinant proteins in Dictyostelium discoideum | |
US7070989B2 (en) | Escherichia coli strain secreting human granulocyte colony stimulating factor (G-CSF) | |
EP0329693A1 (en) | Human pancreatic secretory trypsin inhibitors produced by recombinant dna methods and processes for the production of same | |
RU2144957C1 (ru) | РЕКОМБИНАНТНАЯ ПЛАЗМИДНАЯ ДНК pPINS07, КОДИРУЮЩАЯ ГИБРИДНЫЙ ПОЛИПЕПТИД, СОДЕРЖАЩИЙ ПРОИНСУЛИН ЧЕЛОВЕКА, И ШТАММ БАКТЕРИЙ Escherichia coli - ПРОДУЦЕНТ ГИБРИДНОГО ПОЛИПЕПТИДА, СОДЕРЖАЩЕГО ПРОИНСУЛИН ЧЕЛОВЕКА | |
DK175020B1 (da) | Fremgangsåde til udtrykkelse og ekstracellulær udskillelse af proteiner i G(-)bakterie, rekombinant DNA-konstruktion og plasmidvektor kodende herfor, samt G(-)bakterie indeholdende disse | |
KR940010862B1 (ko) | 유용한 메탈로프로테이나제 억제제 씨퀀스 재조합 벡터계의 제조를 위한 dna 재조합 방법 | |
JP2003526314A (ja) | デンプン結合ドメイン(sbd)の発現 | |
EP0498827B1 (en) | Improved plasmid vectors for cellular slime moulds of the genus dictyostelium | |
EP0264118B1 (en) | Novel method for preparing proteins | |
EP0342658B1 (en) | Biosynthetic process for the preparation of chemical compounds | |
JPH0372888A (ja) | 抗酸菌分泌発現ベクター及び抗酸菌 | |
KR930003913B1 (ko) | 트롬빈 억제 활성을 갖는 폴리펩티드 및 그의 제조방법 | |
Borjaliloo et al. | Comparison of T7-and lac-based systems for the periplasmic expression of human granulocyte macrophage colony stimulating factor in Escherichia coli | |
EP0262805A1 (en) | Stabilised polypeptides and their expression and use in fermentation | |
AU649976B2 (en) | Improved plasmid vectors for cellular slime moulds of the genus dictyostelium |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA FI HU KR NO PL SU US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IT LU NL SE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1991920978 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2082637 Country of ref document: CA |
|
WWP | Wipo information: published in national office |
Ref document number: 1991920978 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1991920978 Country of ref document: EP |